JW Holdings Corporation operates in the Medicinals and botanicals sector.
In addition to historical fundamental analyses, the complete report available to purchase compares JW Holdings with three other
companies in this sector in South Korea:
sales of 158.60 billion Korean Won [US$143.37 million]
of which 91%
Kolon Life Science Incorporation
(158.28 billion Korean Won [US$143.09 million]
of which 45%
was Environment Material), and
Kyongbo Pharmaceutical Co Ltd
(186.73 billion Korean Won [US$168.80 million]
of which 100%
was Drugs & Pharmaceutical Raw Materials).
JW Holdings reported sales of 680.48 billion Korean Won (US$615.15 million)
December of 2016.
increase of 9.3%
versus 2015, when the company's sales were 622.62 billion Korean Won.
This was the fourth straight year of sales growth at JW Holdings.
Sales of Control Business saw an increase
that was more than double the company's growth rate: sales were up
40.2% in 2016, from
17.49 billion Korean Won to 24.53 billion Korean Won.
JW Holdings also saw significant increases in sales in
Medical Equipment (up 29.5% to 104.83 billion Korean Won)
Not all segments of JW Holdings experienced an increase in sales in 2016:
sales of Other Segment fell 4.9% to 27.67 billion Korean Won.
(However, this segment's sales were only a very small portion of the company's overall sales).